Emrelis savings card: as little as $0 an infusion with commercial insurance

Emrelis is given by a doctor or nurse and billed by the clinic, not a pharmacy. Your care team and your insurance decide which product you get, so ask them what you’d pay.

How to pay the least

Given by your care team

Billed by the clinic

Emrelis is given by a doctor or nurse, not picked up at a pharmacy.

Ask your care team or your plan what you’d pay before your visit.

Compare every option

Brand nameEmrelis

Authorized generictelisotuzumab vedotin

Regular generictelisotuzumab vedotin

What you’d pay

Cash priceAsk the pharmacy

Not soldThere isn’t one

Not soldAsk the pharmacy

Same as Emrelis?

The original

–

Brand nameThe maker’s card

EMRELIS Savings Card (co-pay assistance via EMRELIS Support Services)

Savings card from AbbVie

No insuranceNeeds insuranceNo cash price listed.

Insurance · as little as $0 an infusion

The card takes up to $25,000 a year off your co-pay.

Or call 1-844-859-5760.

In the maker’s words

“Commercially insured patients could pay as little as $0 for their medication…”

From the maker’s offer on emrelis.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Authorized genericNot sold

There isn’t one. An authorized generic is Emrelis itself, from the same company, sold without the brand name, and usually for less. For now Emrelis is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

Emrelis is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

Non-small cell lung cancer with high c-Met protein

What the FDA label says

EMRELIS is a c-Met-directed antibody and microtubule inhibitor conjugate indicated for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression [≥50% of tumor cells with strong (3+) staining], as determined by an FDA-approved test, who have received a prior systemic therapy.

This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Source: the FDA label for Emrelis (AbbVie Inc.), May 25, 2025. Full label on DailyMed

Good to know

“Commercial insurance” means a plan from a job, from the marketplace, or one you buy yourself. A retiree plan that’s part of Medicare counts as Medicare. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.
Most cards need a sign-up on the maker’s site, and many work only if your plan covers the drug. Then give the card’s details to the clinic’s billing office.
Don’t stop or change a medicine without talking to your pharmacist or prescriber.

Prices checked November 2, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/emrelis/